|
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.
|
30365556 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The evaluation of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) (β-amyloid, t-tau, p-tau) can be used to estimate the risk of developing dementia in patients at the pre-clinical stages of AD, i.e. subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
|
30509028 |
2018 |
|
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CSF t-tau/Aβ<sub>1-42</sub> ratio had 100% specificity and 90% sensitivity for SYN + AD, and CSF Aβ<sub>1-42</sub> had 77% specificity and 82% sensitivity for neocortical SYN stage.
|
29467305 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the full sample, cortical [<sup>18</sup>F]AV1451 was associated with all CSF biomarkers, most strongly with p-tau (<i>r</i> = 0.75 vs 0.57 for t-tau and -0.49 for Aβ<sub>42</sub>).
|
29282337 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) markers of neurodegeneration [neurofilament light chain (NFL), total Tau (T-Tau)], tau pathology [phosphorylated tau (p-Tau)], glial cell damage or activation [glial fibrillary acidic protein (GFAP)], and brain amyloidosis [β-amyloid 1-42 (Aβ42)] are useful for diagnosis and prognosis in several neurodegenerative disorders.
|
30248592 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker- the CSF total tau/Aβ ratio.
|
28800330 |
2017 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We secondarily hypothesized a third group characterized by either CSF tau pathology or neurodegeneration, in addition to amyloidosis (A+/N+ or Stage 2), would show lower neuropsychology scores than the amyloid positive group (A+/N- or Stage 1) when compared to the amyloid negative group.
|
28497179 |
2017 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic models were constructed by Cox proportional hazards regression with patient characteristics (age, sex, and Mini-Mental State Examination [MMSE] score), magnetic resonance imaging (MRI) biomarkers (hippocampal volume, normalized whole-brain volume), cerebrospinal fluid (CSF) biomarkers (amyloid-β1-42, tau), and combined biomarkers.
|
29049480 |
2017 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined whether neuropsychiatric symptoms (NPS) interact with cerebrospinal fluid (CSF) biomarkers (amyloid-β42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, and ptau181/Aβ42) of Alzheimer's disease pathology to predict driving decline among cognitively-normal older adults (N = 116) aged ≥65.
|
28453487 |
2017 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-β42, high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice.
|
28413821 |
2017 |
|
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased levels of CSF Aβ<sub>40</sub> and Aβ<sub>42</sub> occur before HCHWA-D mutation carriers develop clinical symptoms, implicating vascular deposition of both Aβ species as early steps in cerebral amyloid angiopathy pathogenesis.
|
27903811 |
2017 |